Novel therapies for inflammatory bowel disease

被引：27

作者：

Sands, BE

机构：

[1] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA

[2] Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA

[3] Harvard Univ, Sch Med, Boston, MA USA

来源：

GASTROENTEROLOGY CLINICS OF NORTH AMERICA | 1999年 / 28卷 / 02期

关键词：

D O I：

10.1016/S0889-8553(05)70059-5

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Recent advances in our understanding of the basic processes that contribute to inflammatory bowel disease have led to the identification of new targets for therapy Novel therapies, which include agents in development and those newly introduced for use in the clinic, include both traditional compounds and a growing number of biologic response modifiers. This article places these novel therapies within a pathophysiologic framework, highlighting completely new targets and therapeutic modalities.

引用

页码：323 / +

页数：30

共 218 条

[1] Soluble recombinant human P-selection glycoprotein ligand-1 (sPSGL-1), decreases intestinal lesions in HLA-B27 transgenic rats and in acetic acid-induced colitis in Sprague-Dawley rats. [J].